Pharmaceuticals

Rising cancer and infectious diseases are fueling the Viral Vector Manufacturing Market 2026

March 25, 2026March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Viral Vector Manufacturing Market By The End Of 2030?

The viral vector manufacturing market has experienced substantial growth in recent years. This market is projected to expand from $8.26 billion in 2025 to $9.9 billion in 2026, at a compound annual growth rate (CAGR) of 19.9%. Historically, this expansion was influenced by factors such as limited manufacturing capacity, high production cost, reliance on traditional gene delivery methods, regulatory barriers, and fragmented supply chains.

The viral vector manufacturing market size is anticipated to experience substantial expansion in the coming years. This market is projected to reach $21.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 21.1%. The expansion during the forecast period is fueled by several factors, including the increasing need for gene and cell therapies, technological improvements in viral vectors, greater investments in research and development, the growth of contract manufacturing organizations, and the increasing uptake of personalized medicine. Key developments expected within this period involve innovations in gene therapy, refining viral vector safety, developing scalable manufacturing processes, improving regulatory adherence, and enhancing upstream and downstream processing techniques.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What Primary Drivers Are Shaping The Development Of The Viral Vector Manufacturing Market?

The anticipated expansion of the viral vector manufacturing market is linked to the rising incidence of cancer and infectious diseases. An infectious disease is defined as an ailment caused by a virus or its harmful substances, which can be transmitted to a vulnerable host through interaction with an infected individual, animal, or object. Cancer encompasses various conditions where abnormal cells proliferate uncontrollably in any organ or tissue, exceeding their normal limits to invade adjacent organs and metastasize to distant parts of the body. Viral vectors are utilized to generate tumor antigens, which are proteins found on tumor cells, thereby stimulating the body’s immune system to combat cancer. Furthermore, viral vectors have been employed as vaccines against diverse infectious illnesses in both pre-clinical and clinical investigations. As an illustration, data from July 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, shows that in Australia, cancer diagnoses climbed from 160,570 in 2022 to 164,694 in 2023, indicating a significant annual increase. This escalating trend underscores the increasing occurrence of cancer nationwide. Moreover, information released in August 2024 by the UK Health Security Agency, a UK-based executive agency, indicated that in England, the UK Health Security Agency (UKHSA) recorded 368 measles cases in 2023, representing an almost sevenfold jump from the 53 cases in 2022, with 44% of cases occurring in the West Midlands and 33% in London. Consequently, the rising prevalence of both cancer and infectious diseases is a key factor propelling the expansion of the viral vector manufacturing market.

Which Segment Classifications Shape The Viral Vector Manufacturing Market?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Other End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

How Are Trends Impacting The Viral Vector Manufacturing Market?

Leading companies within the viral vector manufacturing market are prioritizing the creation of advanced products, specifically viral vector platforms tailored for viral vector production and manufacturing. These viral vector platforms are comprehensive systems designed to efficiently produce and process viral vectors for applications such as gene therapy and vaccine development. For example, in May 2023, AGC Biologics, a US-based global biopharmaceutical contract development and manufacturing organization (CDMO), introduced its BravoAAV and ProntoLVV platforms. These platforms are designed to offer flexible and accelerated vector development and manufacturing for cell and gene therapy programs, ensuring GMP product delivery in nine months, supported by a global regulatory and supply network and in-house plasmid DNA services. With custom processes, templated material approaches, and prequalified analytical methods, these platforms are significant contributors to the viral vector manufacturing market’s projected growth, reaching $5.5 billion by 2035, by addressing the increasing demand for efficient development and delivery of life-changing gene therapies and vaccines.

Which Companies Are Expanding Their Footprint In The Viral Vector Manufacturing Market?

Major companies operating in the viral vector manufacturing market are Sanofi S.A., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV

Read the full viral vector manufacturing market report here:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

How Does The Viral Vector Manufacturing Market Perform Across Major Global Regions?

North America was the largest region in the viral vector manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Viral Vector Manufacturing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

Browse Through More Reports Similar to the Global Viral Vector Manufacturing Market 2026, By The Business Research Company

Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Viral And Non Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795